Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 9/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | THPO | P40225 | 1/20 | 0.79 |
| ▸ | MTOR | P42345 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
| ▸ | DRD2 | P14416 | 4/20 | 0.66 |
| ▸ | HTR2A | P28223 | 2/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9378627 | 0.91 | SIGMAR1 (1.00) | SIGMAR1HTR1AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL14410956 | 0.88 | HTR1A (1.00) | SIGMAR1HTR1AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL31513986 | 0.88 | ALDH1A1 (1.00) | SIGMAR1HTR1AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3976547 | 0.88 | ALDH1A1 (1.00) | SIGMAR1HTR1AALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL15263292 | 0.87 | ALDH1A1 (0.98) | SIGMAR1HTR1AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL10900911 | 0.87 | SIGMAR1 (0.76) | SIGMAR1HTR1AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6864697 | 0.86 | SIGMAR1 (0.76) | SIGMAR1HTR1AALDH1A1TSHRTDP1 | |
| SCHEMBL11465528 | 0.84 | SIGMAR1 (0.76) | SIGMAR1HTR1AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL13959478 | 0.84 | SIGMAR1 (0.72) | SIGMAR1HTR1AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1298949 | 0.82 | SIGMAR1 (0.70) | SIGMAR1HTR1AALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | claimed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | claimed |
| WO-1991009594-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1991-07-11 | — | — | WO | claimed |
| US-RE46117-E1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2016-08-23 | — | — | US | disclosed |
| EP-1428822-B1 | 1-phenylpiperazine derivative as modulators of dopamine neurotransmission | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2010-12-15 | — | — | EP | disclosed |
| US-7417043-B2 | Modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2008-08-26 | — | — | US | disclosed |
| EP-1341777-B1 | 1-(2-M-METHANESULFONAMIDOPHENYLETHYL)-4-(M-TRIFLUOROMETHYLPHENYL)PIPERAZINE AND PHARMACEUTICALLY ACCEPTABLE SALTS AND SOLVATES THEREOF AND THEIR USE IN THE TREATEMENT OF INCONTINENCE | LILLY CO ELI (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20060135531-A1 | Modulators of dopamine neurotransmission | A. CARLSSON RESEARCH AB (SE) | 2006-06-22 | — | — | US | disclosed |
| EP-1240142-B1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | CARLSSON A RESEARCH AB (SE) | 2005-10-19 | — | — | EP | disclosed |
| US-6903120-B2 | A 4-(phenyl-N- alkyl)-piperidine derivatives for treatment of central nervous system disorders, Parkinson disease, anxiety, dyskinesias, dystonias, Tourette's disease, psychoses, hallucinoses, sleep disorder, autism | A. CARLSSON RESEARCH AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1428822-A2 | 1-phenylpiperazine derivative as modulators of dopamine neurotransmission | A. Carlsson Research AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| US-20030139423-A1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2003-07-24 | — | — | US | disclosed |
| EP-1240142-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. Carlsson Research AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| US-6313297-B1 | CATALYTIC ALKYLATION; BY-PRODUCT INHIBITION | AVENTIS RESEARCH & TECHNOLOGIES (DE) | 2001-11-06 | — | — | US | disclosed |
| WO-2001046145-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| EP-1047680-A2 | BASE-CATALYZED SYNTHESIS OF 1-ARYL-4-(ARYL ETHYL)PIPERAZINES FROM AROMATIC OLEFINS AND 1-ARYL PIPERAZINES | Aventis Research & Technologies GmbH & Co KG (DE) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999036412-A2 | BASE-CATALYZED SYNTHESIS OF 1-ARYL-4-(ARYL ETHYL)PIPERAZINES FROM AROMATIC OLEFINS AND 1-ARYL PIPERAZINES | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135531-A1 | Modulators of dopamine neurotransmission | SLC6A3, BRS3, CHRNA3 | SIGMAR1 54/4885HTR1A 152/4885ALDH1A1 2313/4885 |
| US-20030139423-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | SIGMAR1 9/4885HTR1A 90/4885ALDH1A1 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.